|
Market Closed -
Nasdaq
04:00:00 2025-08-14 pm EDT
|
5-day change | 1st Jan Change | ||
| 100.99 USD | +0.01% |
|
-.--% | - |
| Market Cap | 3.32B 2.91B 2.75B 2.51B 4.7B 318B 4.73B 32.94B 12.76B 163B 12.47B 12.2B 523B | P/E 2023 |
-317x | P/E 2024 | 69.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.48B 3.05B 2.88B 2.63B 4.92B 333B 4.95B 34.49B 13.36B 170B 13.06B 12.77B 547B | EV / Sales 2023 |
1.55x | EV / Sales 2024 | 1.33x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 25-09-30 | A CEO's Playbook For Navigating Crisis And Building Trust (Video) | AQ |
| 25-07-29 | Amedisys: Q2 Earnings Snapshot | AQ |
| 25-07-29 | Amedisys : Second Quarter 2025 Earnings Release Supplemental Slides | PU |
| 25-07-29 | Amedisys Reports Second Quarter 2025 Financial Results | AQ |
| 25-04-23 | Amedisys: Q1 Earnings Snapshot | AQ |
| 1 day | +0.01% |
| 3 years | 82.15 |  | 101.02 |
| 5 years | 69.36 | | 188.88 |
| 10 years | 34.58 | | 325.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Ginn
DFI | Director of Finance/CFO | 57 | 2017-10-05 |
Keith Blanchard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Denise Bohnert
CMP | Compliance Officer | 48 | 2016-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/14/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 8/14/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 8/14/25 | Issuer sale | Chief Executive Officer | 520,347 | 1.5886% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 2.24B 1.96B 1.85B 1.69B 3.16B 214B 3.18B 22.18B 8.59B 110B 8.4B 8.22B 352B | 2.35B 2.06B 1.95B 1.77B 3.32B 225B 3.34B 23.29B 9.02B 115B 8.82B 8.63B 370B |
| Net income | -9.75M -8.55M -8.08M -7.36M -13.78M -934M -13.88M -96.67M -37.44M -477M -36.6M -35.8M -1.53B | 43.23M 37.94M 35.83M 32.65M 61.12M 4.14B 61.56M 429M 166M 2.12B 162M 159M 6.8B |
| Net Debt | 361M 317M 299M 272M 510M 34.58B 514M 3.58B 1.39B 17.66B 1.35B 1.33B 56.77B | 156M 137M 129M 118M 221M 14.96B 222M 1.55B 599M 7.64B 586M 573M 24.56B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMED Stock
Select your edition
All financial news and data tailored to specific country editions
